ACADIA Pharmaceuticals Inc. vs C3.ai Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while C3.ai Inc trades at $10.59 (market cap $1.59B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3.2× C3.ai Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | AI | |
|---|---|---|
Market Cap | $5.06B | $1.59B |
Sector | Health | Technology |
52-Week High | $29.41 | $19.66 |
52-Week Low | $20.06 | $7.76 |
Enterprise Value | $4.18B | $1.02B |
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →